Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

18.19 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 54
Open 18.19
Bid (Size) 17.75 (1)
Ask (Size) 19.91 (1)
Prev. Close 18.19
Today's Range 18.19 - 18.19
52wk Range 8.700 - 20.54
Shares Outstanding 122,816,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NeoGenomics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Utility of RaDaR for Therapy Response
Via ACCESSWIRE
NeoGenomics to Participate at the Piper Sandler 35th Annual Healthcare Conference
Via ACCESSWIRE

Performance

YTD
+100.11%
+100.11%
1 Month
+24.16%
+24.16%
3 Month
+27.56%
+27.56%
6 Month
+4.30%
+4.30%
1 Year
+57.35%
+57.35%

More News

Read More
What 6 Analyst Ratings Have To Say About NeoGenomics
Via Benzinga
NeoGenomics Reports Third Quarter 2023 Results
Via ACCESSWIRE
Earnings Scheduled For November 6, 2023
Via Benzinga
Bull Of The Day: NeoGenomics
Via Talk Markets
NeoGenomics Announces the Commercial Availability of Two New Tests, Expanding Its Next-Generation Sequencing and Lung Cancer Portfolios
Via ACCESSWIRE
Where NeoGenomics Stands With Analysts
Via Benzinga
4 Analysts Have This to Say About NeoGenomics
Via Benzinga
NeoGenomics Raises Annual Guidance After Solid Q2 Earnings Beat
Via Benzinga
NeoGenomics to Report Third Quarter 2023 Financial Results on November 6, 2023
Via ACCESSWIRE
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
Via FinancialNewsMedia
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Earnings Scheduled For August 11, 2023
Via Benzinga
NeoGenomics Reports Second Quarter 2023 Results
Via ACCESSWIRE
NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer
Via ACCESSWIRE
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
Via ACCESSWIRE
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
Via ACCESSWIRE
Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Via ACCESSWIRE
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
Via ACCESSWIRE
NeoGenomics's Return On Capital Employed Insights
Via Benzinga
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Via ACCESSWIRE
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.